approxim
million
peopl
global
chronic
infect
hepat
c
viru
hcv
signific
number
chronic
infect
develop
cirrhosi
hepatocellular
carcinoma
liver
failur
result
approxim
death
year
recent
approv
combin
regimen
daa
sofosbuvir
sof
plu
ledipasvir
velpatasvir
glecaprevir
plu
pibrentasvir
drastic
improv
efficaci
outcom
decreas
treatment
side
effect
compar
interferoncontain
regimen
past
inde
regimen
produc
sustain
virolog
respons
svr
rate
greater
treatment
durat
week
depend
regimen
patient
popul
result
sustain
virolog
cure
despit
recent
advanc
signific
challeng
remain
manag
difficulttotreat
popul
includ
hcv
genotyp
gt
infect
cirrhosi
prior
treatment
experi
popul
typic
requir
least
week
treatment
often
combin
ribavirin
increas
risk
seriou
side
effect
abl
receiv
treatment
regimen
contain
proteas
inhibitor
due
advanc
liver
diseas
therefor
ideal
regimen
would
high
efficaci
base
shorter
treatment
durat
patient
popul
improv
safeti
profil
includ
less
drugdrug
interact
potenti
compar
current
approv
regimen
treatment
hcv
daa
develop
target
differ
critic
step
hcv
life
cycl
one
target
interest
rnadepend
rna
polymeras
rdrp
encod
region
hcv
genom
essenti
viral
replic
thu
nucleotid
analog
convert
triphosph
analog
within
cell
incorpor
nascent
hcv
rna
block
viral
replic
prefer
candid
sinc
proven
potent
pangenotyp
inhibitor
high
barrier
drug
resist
addit
appar
improv
antivir
activ
guanosin
analog
compar
pyrimidin
analog
sof
prompt
search
modifi
guanosin
analog
contain
proven
substitut
ribos
moieti
monophosph
prodrug
previous
identifi
guanosin
analog
cyclic
phosphat
prodrug
monophosph
prodrug
monophosph
excel
activ
hcv
replic
develop
halt
due
observ
hepat
cardiac
toxic
respect
structur
sof
well
structurallyrel
hcv
inhibitor
show
potent
vitro
activ
hcv
present
fig
present
develop
whose
put
metabol
pathway
present
fig
hemisulf
salt
phosphoramid
prodrug
monophosph
phosphoramid
moieti
ident
sof
presum
subject
initi
metabol
activ
pathway
lead
uniqu
nucleotid
monophosph
mp
still
contain
modif
hydrolysi
catalyz
human
cathepsin
cata
andor
carboxylesteras
produc
lalanyl
intermedi
follow
remov
amino
acid
moieti
histidin
triad
nucleotidebind
protein
result
mp
metabolit
like
convert
adenosin
deaminas
like
protein
anabol
sequenti
guanyl
kinas
nucleosid
diphosph
kinas
ndpk
pharmacolog
activ
triphosph
tp
presum
dephosphoryl
nucleotidas
ntase
respect
nucleosid
fig
thu
possess
uniqu
structur
featur
group
critic
differenti
guanosin
nucleotid
analog
respect
drug
metabol
provid
compound
favor
preclin
safeti
profil
maintain
highli
potent
antivir
activ
support
clinic
develop
free
base
use
vitro
experi
measur
effect
concentr
viru
replic
inhibit
concentr
requir
produc
toxic
effect
expos
cell
salt
form
use
anim
studi
increas
aqueou
solubl
thu
enhanc
oral
absorpt
initi
experi
hcv
replicon
system
stabli
transfect
cell
use
evalu
antihcv
activ
cytotox
use
britelit
xtt
reagent
respect
sof
use
posit
control
mean
valu
nm
rang
nm
mean
valu
nm
rang
nm
six
differ
blind
batch
n
determin
gave
mean
valu
nm
rang
nm
mean
valu
nm
rang
nm
demonstr
roughli
potent
sof
fig
tabl
neither
sof
show
toxic
replicon
cell
highest
concentr
test
sof
antivir
activ
sof
also
determin
use
replicon
cell
stablytransfect
region
hcv
hcv
genotyp
phenosens
hcv
assay
concentr
sof
need
achiev
level
laboratori
strain
nm
respect
time
greater
nm
respect
tabl
addit
five
cell
line
contain
region
variou
hcv
genotyp
test
sof
tabl
similar
refer
viru
valu
averag
higher
sof
higher
compar
potenc
ratio
rang
differ
strain
addit
rang
valu
sof
nm
across
genotyp
test
compar
tighter
rang
nm
addit
valu
across
eight
differ
replicon
transientlytransfect
region
hcv
deriv
clinic
isol
variou
genotyp
averag
higher
sof
potenc
ratio
rang
tabl
rang
sof
valu
nm
wherea
cover
rang
nm
potenc
ratio
variabl
nm
sof
nm
similar
across
patientderiv
genotyp
well
tabl
result
demonstr
exhibit
pangenotyp
antihcv
activ
consist
potent
sof
hcv
genotyp
test
sever
hcv
laboratori
strain
clinic
isol
contain
resistanceassoci
variant
rav
test
use
phenosens
assay
valu
respect
higher
sof
compar
except
three
strain
contain
genet
variat
tabl
polymorph
sof
significantli
less
effect
inhibit
viral
replic
compar
respons
use
refer
strain
lack
variant
requir
drug
achiev
level
respect
hand
shift
valu
respect
therefor
show
littl
evid
crossresist
hcv
strain
test
significantli
potent
sof
rav
contain
variant
test
specif
panel
select
rna
dna
virus
incub
drug
concentr
valu
compar
respons
control
compound
effect
virus
tabl
wherea
nanomolar
level
strongli
inhibit
hcv
much
higher
concentr
result
weak
activ
zika
viru
human
rhinoviru
hrv
activ
rna
dna
virus
tabl
potent
specif
inhibitor
hcv
rdrp
vitro
inhibitori
concentr
mean
two
assay
test
altern
substrat
gtp
wherea
weakli
inhibit
polymeras
singl
assay
competit
inhibitor
atp
moreov
inact
test
inhibitor
human
dna
polymeras
compar
valu
observ
respect
posit
control
aphidicolin
lithochol
acid
dgtp
sinc
toxic
sever
nucleosid
triphosph
analog
thought
result
abil
inhibit
human
mitochondri
rna
polymeras
polrmt
thu
disrupt
mitochondri
rna
transcript
protein
synthesi
potenti
inhibit
polrmt
assess
parallel
activ
tp
sof
cmethyl
utp
activ
tp
cmethyl
gtp
drug
known
caus
toxic
via
inhibit
polrmt
although
activ
form
three
drug
util
polrmt
vitro
incorpor
prevent
subsequ
cycl
nucleotid
addit
fig
effici
incorpor
kpolkd
app
poor
compar
correspond
natur
nucleotid
tabl
incorpor
effici
sof
tp
within
twofold
wherea
tp
incorpor
polrmt
time
effici
sof
tp
determin
whether
minim
interact
polrmt
could
result
deleteri
effect
mitochondri
function
incub
cell
cell
cultur
medium
galactos
substitut
glucos
therebi
assess
abil
mitochondri
electron
transport
system
maintain
cellular
atp
level
without
contribut
glycolysi
measur
mitochondri
toxic
membran
integr
inhibit
cellular
atp
level
assess
compar
cell
incub
glucosecontain
medium
concentr
cytotox
alter
cell
membran
integr
affect
mitochondri
function
presenc
absenc
galactos
tabl
posit
control
compound
digitonin
induc
necrosi
affect
mitochondri
function
presenc
glucos
well
absenc
cccp
permeabil
mitochondri
inner
membran
inhibit
cellular
atp
level
cell
presenc
glucos
sever
absenc
tabl
attempt
assess
mitochondri
toxic
effect
mitochondri
biogenesi
cell
assess
measur
level
nucleardnaencod
sdha
protein
mitochondrialdnaencod
protein
day
treatment
concentr
cytotox
effect
express
level
either
protein
tabl
digitonin
cccp
gener
cytotox
cell
wherea
chloramphenicol
arrest
mitochondri
protein
synthesi
ddc
inhibit
mitochondri
dna
replic
select
reduc
level
tabl
addit
cell
line
list
tabl
show
cytotox
highest
concentr
test
antivir
replicon
assay
incub
mous
rat
dog
monkey
human
hepatocyt
cytotox
evalu
human
induc
pluripot
stem
cell
ip
cardiomyocyt
granulocyt
macrophag
gm
erythroid
e
human
bone
marrow
progenitor
cell
show
toxic
cardiomyocyt
bone
marrow
stem
cell
assay
wherea
posit
control
compound
expect
cytotox
effect
valu
doxazosin
cardiomyocyt
azt
gm
e
cell
assay
respect
prodrug
discontinu
fail
due
toxic
clinic
like
due
format
mutagen
nucleobas
metabolit
format
metabolit
assess
separ
incub
initi
concentr
recombin
human
cytochrom
presenc
nadph
form
low
level
mean
sd
tabl
guanin
detect
incub
medium
contain
would
expect
uniqu
structur
fig
form
form
respect
result
indic
start
drug
concentr
convert
known
mutagen
base
nucleobas
form
total
convert
modifi
nucleobas
determin
inhibit
cytochrom
cyp
enzym
panel
substrat
select
seven
cyp
isozym
separ
ad
liver
microsom
incub
hcv
inhibitor
valu
highest
concentr
test
weakli
inhibit
compar
inhibitor
use
posit
control
enzym
whose
valu
rang
tabl
therefor
low
potenti
drugdrug
interact
mediat
cyp
enzym
metabol
character
cell
human
hepatocarcinoma
cell
line
use
construct
hcv
replicon
measur
antivir
activ
mous
rat
dog
monkey
human
hepatocyt
absenc
cell
stabl
incub
cultur
medium
h
predomin
intracellular
metabolit
measur
hepatocyt
speci
cell
incub
fig
except
mous
hepatocyt
far
exceed
intracellular
concentr
demonstr
activ
tp
effici
form
phosphoramid
protid
liver
cell
hepatocyt
incub
rel
level
form
accumul
h
express
area
curv
tabl
least
abund
rat
human
mous
dogmonkey
tp
fig
still
contain
moieti
purin
ring
detect
fact
quantifi
tp
found
hepatocyt
time
point
predomin
mp
metabolit
observ
cell
hepatocyt
except
mous
lower
amount
mp
detect
consist
hypothesi
phosphoramid
metabol
turn
effici
oxid
deamin
prior
stepwis
phosphoryl
activ
tp
low
undetect
intracellular
level
cell
nucleosid
metabolit
presum
form
dephosphoryl
observ
mous
dog
human
hepatocyt
measur
monkey
hepatocyt
human
hepatocyt
incub
h
time
point
maximum
concentr
observ
follow
washout
period
h
halflif
h
support
potenti
daili
dose
patient
individu
plasma
concentr
singl
oral
administr
hemisulf
salt
rat
mgkg
monkey
mgkg
tabl
use
calcul
mean
pharmacokinet
paramet
summar
tabl
phosphoryl
metabolit
form
retain
intracellularli
due
neg
charg
includ
mp
activ
tp
intermedi
diphosph
dp
fig
measur
plasma
sampl
level
phosphoryl
metabolit
quantit
sampl
liver
heart
tissu
obtain
h
dose
rat
monkey
rat
n
per
sex
rapidli
absorb
effici
convert
lalanyl
metabolit
evidenc
rel
tmax
cmax
valu
tabl
fig
tabl
nucleosid
metabolit
mp
still
contain
modif
peak
roughli
hour
later
nucleosid
metabolit
form
dephosphoryl
dp
mp
form
thu
measur
intracellular
format
phosphat
longest
mean
resid
time
mrt
measur
averag
time
molecul
spend
circul
h
apart
level
somewhat
higher
femal
rat
obviou
gender
differ
mean
valu
sd
combin
data
sex
present
plasma
profil
male
monkey
n
per
dose
similar
rat
fig
mean
valu
increas
nearli
dose
proport
system
exposur
rose
increas
dose
data
reflect
rapid
absorpt
effici
convers
suggest
elimin
nucleosid
metabolit
like
via
renal
excret
satur
dose
increas
longest
mrt
administr
three
dose
level
tabl
indic
long
halflif
activ
tp
form
intracellularli
rat
n
per
sex
h
mgkg
oral
dose
mean
concentr
activ
tp
pmolg
higher
heart
pmolg
similarli
mean
liverheart
concentr
ratio
male
monkey
hr
oral
dose
mgkg
n
per
dose
tabl
indic
preferenti
format
activ
tp
liver
speci
fact
heart
tissu
except
one
rat
dose
mgkg
concentr
estim
extrapol
calibr
curv
lower
limit
quantit
lloq
lcmsm
assay
pmolg
moreov
observ
hepatocyt
cell
activ
tp
predomin
metabolit
measur
monkey
liver
mgkg
concentr
dose
proport
pmolg
respect
tabl
lower
therapeut
relev
dose
mgkg
mean
liver
concentr
higher
parent
phosphoramid
demonstr
effici
convers
activ
tp
liver
cell
monkey
liver
mgkg
dose
compar
mgkg
dose
suggest
convers
via
esteras
activ
becom
satur
high
dose
nevertheless
even
high
dose
concentr
time
higher
liver
compar
correspond
heart
tissu
addit
high
liverheart
ratio
monkey
similarli
high
ratio
monophosph
precursor
evid
compound
preferenti
deliv
liver
target
organ
hcv
infect
observ
hepatocyt
speci
test
tp
either
detect
monkey
liver
heart
tissu
possibl
present
trace
level
well
lloq
assay
pmolg
dose
proportion
monkey
liver
mgkg
dose
reflect
plasma
level
fold
increas
respect
cmax
valu
increas
dose
consist
form
via
dephosphoryl
phosphoryl
form
fig
sinc
predomin
intracellular
phosphoryl
metabolit
consid
plasma
marker
intracellular
level
activ
triphosph
free
base
new
drug
candid
significantli
potent
vitro
hcv
genotyp
test
compar
sof
current
approv
nucleosid
inhibitor
treatment
hcv
infect
compar
sof
time
potent
difficulttotreat
moreov
time
potent
sof
rav
contain
polymorph
least
potent
suggest
may
potenti
demonstr
greater
clinic
antivir
activ
two
nucleotid
prodrug
result
consist
high
intracellular
format
activ
triphosph
metabolit
cell
human
hepatocyt
vivo
monkey
rat
studi
demonstr
effici
absorb
dose
oral
hemisulf
salt
extens
convert
activ
tp
liver
target
hcv
infect
despit
rel
low
concentr
rat
plasma
oral
administr
observ
consist
known
high
level
esteras
activ
rodent
blood
speci
produc
one
highest
amount
activ
tp
hepatocyt
incub
vitro
well
liver
concentr
vivo
addit
rat
monkey
studi
show
oral
administr
singl
dose
result
preferenti
deliveri
monophosph
precursor
liver
activ
tp
predomin
intracellular
phosphoryl
metabolit
form
potent
antivir
activ
appear
rel
specif
hcv
sinc
drug
show
weak
measur
activ
panel
virus
lack
activ
dna
virus
adenoviru
hbv
contain
rna
genom
requir
revers
transcript
dna
may
attribut
dissimilar
polymeras
involv
replic
virus
compar
hcv
positivesens
singlestrand
rna
viru
appar
specif
singlestrand
rna
virus
test
howev
suggest
differ
polymeras
relat
virus
render
rel
resist
inhibit
nevertheless
potenc
across
hcv
genotyp
test
speak
highli
conserv
natur
hcv
genom
region
sinc
certain
purin
substrat
unsubstitut
mp
group
present
unlik
moieti
either
convert
directli
correspond
guanosin
analog
similarli
like
form
via
dephosphoryl
mono
di
triphosphoryl
form
activ
tp
form
retain
intracellularli
level
directli
measur
blood
sampl
howev
abund
metabolit
form
cell
hepatocyt
vitro
liver
tissu
vivo
plasma
level
regard
surrog
intracellular
level
activ
tp
thu
h
halflif
observ
human
hepatocyt
vitro
well
prolong
mrt
plasma
rat
monkey
administr
singl
oral
dose
consist
daili
oral
dose
treatment
hcv
infect
arnold
colleagu
report
antivir
ribonucleosid
tp
analog
test
includ
sof
tp
incorpor
polrmt
extent
wherea
mitochondri
toxic
report
sof
rapid
develop
cardiac
toxic
observ
clinic
trial
attribut
abil
activ
tp
inhibit
polrmt
concentr
lower
requir
tp
sof
demonstr
herein
previous
report
sof
undoubtedli
substitut
sof
replac
natur
occur
group
reason
far
lower
substrat
effici
tp
sof
polrmt
compar
tp
assess
potenti
caus
mitochondri
toxic
multipl
vitro
test
conduct
glucosegalactos
cytotox
assay
cell
detect
chang
mitochondri
function
although
assay
wide
use
detect
mitochondri
toxic
sever
investig
found
limit
valu
known
mitochondri
toxin
ddc
gener
cytotox
galactoseadapt
cell
howev
lack
toxic
observ
mitobiogenesi
assay
conduct
cell
reassur
cell
sensit
mitochondri
toxic
mitochondri
protein
synthesi
assay
wellaccept
evalu
nucleosid
analog
moreov
cytotox
ip
cardiomyocyt
bone
marrow
progenitor
cell
indic
drug
cardiotox
myelosuppress
effect
observ
nucleosid
analog
prodrug
monophosph
previous
develop
includ
phosphoramid
prodrug
mp
cyclic
mp
prodrug
despit
potent
clinic
antihcv
activ
latter
drug
develop
compound
discontinu
halt
due
hepat
toxic
observ
extend
dose
clinic
earli
prodrug
share
similar
modif
nucleobas
subject
metabol
pathway
lead
format
mutagen
metabolit
methyl
ethyl
substitut
posit
guanin
possess
uniqu
structur
featur
group
critic
differenti
respect
metabol
result
studi
highlight
differ
sinc
unlik
mutagen
base
form
convert
modifi
nucleobas
thu
mitig
hepatotox
risk
moreov
almost
inhibitori
effect
panel
cytochrom
enzym
appear
low
potenti
metabol
drugdrug
interact
potent
pangenotyp
antivir
activ
favor
preclin
safeti
profil
compar
highli
inhibitori
protid
gtp
analog
potenti
effect
compon
hcv
therapi
achiev
high
svr
rate
patient
popul
regardless
genotyp
stage
diseas
possibl
shorten
treatment
durat
would
greatli
improv
eas
use
burden
patient
chronic
hcv
infect
batch
provid
atea
pharmaceut
inc
solubil
dmso
mm
atea
also
provid
activ
triphosph
metabolit
sof
cmethyl
utp
cmethyl
gtp
mm
aqueou
solut
mitochondri
assay
mm
refer
standard
cytochrom
metabol
studi
variou
mono
triphosph
refer
standard
assess
level
liver
heart
tissu
test
compound
variou
vitro
antivir
select
assay
evalu
use
top
test
concentr
either
five
serial
dilut
triplic
approv
antihcv
nucleosid
analog
sof
purchas
sigma
aldrich
st
loui
mo
compar
sever
studi
unless
otherwis
state
posit
control
compound
obtain
sigma
aldrich
replicon
harbor
hcv
code
sequenc
huhlucneoet
cell
harbor
persist
replic
et
replicon
contain
firefli
luciferas
geneubiquitinneomycin
phosphotransferas
fusion
protein
emcv
ire
driven
hcv
code
sequenc
contain
et
tissu
cultur
adapt
mutat
seed
plate
cellswel
incub
dmem
supplement
fc
mm
glutamin
penicillin
iuml
streptomycin
nonessenti
amino
acid
plu
mgml
antibiot
h
media
replac
media
minu
plu
test
compound
triplic
six
well
plate
receiv
media
alon
notreat
control
cell
incub
addit
h
antihcv
activ
measur
use
britelit
plu
luminesc
report
gene
kit
accord
manufactur
instruct
perkin
elmer
shelton
ct
duplic
plate
treat
incub
parallel
assess
cellular
toxic
xtt
stain
result
data
use
determin
test
articl
concentr
requir
inhibit
viru
replic
reduc
cell
viabil
phenosens
hcv
assay
assay
develop
monogram
bioscienc
san
francisco
ca
use
determin
suscept
variou
hcv
replicon
resist
test
vector
rtv
posit
control
sof
rtv
contain
code
region
hcv
prepar
laboratori
strain
well
strain
deriv
patient
clinic
isol
identifi
genotyp
resistanceassoci
variant
rav
use
quantit
measur
differ
inhibitor
suscept
rel
drug
suscept
refer
replicon
prepar
rtv
rna
describ
protocol
rtv
rna
electropor
cell
incub
presenc
absenc
inhibitor
h
replic
capac
determin
evalu
luciferas
activ
later
time
point
absenc
inhibitor
rel
control
refer
replicon
rtv
hcv
genotyp
replic
defect
replicon
util
determin
assay
background
percent
inhibit
serial
dilut
inhibitor
concentr
deriv
follow
inhibitor
suscept
curv
deriv
valu
inhibit
data
interpol
report
foldchang
rel
refer
cell
viabil
determin
use
assay
accord
manufactur
instruct
invitrogen
carlsbad
ca
antivir
assay
differ
cell
virus
prepar
specifi
protocol
assay
run
microtit
plate
contain
cell
control
well
cell
viru
control
well
cell
viru
drug
toxic
well
cell
drug
drug
background
well
drug
experiment
well
drug
posit
control
cell
viru
sampl
test
triplic
five
halflog
dilut
per
compound
cell
virus
drug
ad
plate
incub
antivir
cell
viabil
assay
conduct
describ
protocol
replicon
cell
replicon
harbor
hcv
code
sequenc
use
hcv
inhibit
assay
incub
plate
cellswel
h
time
point
media
remov
cell
wash
twice
cold
pb
collect
ml
cold
meoh
extract
overnight
intern
standard
ad
centrifug
g
min
supernat
analyz
concentr
metabolit
lcmsm
describ
protocol
untreat
cell
collect
time
point
neg
control
hepatocyt
plate
cryopreserv
hepatocyt
human
mix
gender
pool
donor
male
spragu
dawley
rat
male
cynomolgu
monkey
purchas
sekisui
xenotech
kansa
citi
ks
plate
matrigel
overlay
plate
maintain
overnight
medium
contain
penstrep
antibiot
xenotech
cryopreserv
male
mous
fresh
male
beagl
dog
male
cynomolgu
monkey
hepatocyt
obtain
bioreclamationivt
baltimor
md
similarli
plate
matrigel
plate
maintain
overnight
medium
antibiot
bioreclamationivt
protocol
describ
measur
metabolit
cell
repeat
five
differ
hepatocyt
untreat
cell
collect
h
protein
content
cell
lysat
determin
use
bicinchonin
acid
protein
assay
kit
assess
number
cell
incub
separ
plate
human
hepatocyt
incub
h
follow
washout
period
h
cell
wash
lyse
ml
cold
meoh
overnight
lysat
collect
determin
halflif
activ
metabolit
lcmsm
describ
analysi
triphosph
protocol
rdrp
activ
determin
incorpor
radiolabel
ribonucleotid
synthes
rna
rdrp
reaction
mixtur
contain
trishcl
ph
kcl
nacl
dtt
utp
vitro
transcrib
rna
templat
complementari
hcv
strand
region
rctp
ratp
rgtp
reduc
amount
give
posit
inhibitori
respons
particular
nucleotid
analog
evalu
enzym
deriv
prepar
southern
research
frederick
md
ad
serial
dilut
plate
h
incub
extens
wash
radioact
measur
micropl
scintil
counter
use
determin
potenc
compound
inhibit
southern
research
frederick
md
use
posit
control
assay
polymeras
purchas
chimerx
madison
wi
inhibit
dna
polymeras
activ
assay
microtit
plate
mm
trishcl
ph
mm
mg
acet
mgml
bsa
dtt
mm
spermin
mm
dctp
dttp
datp
cimmol
activ
calf
thymu
dna
test
compound
indic
concentr
dna
polymeras
reaction
mixtur
contain
mm
trishcl
ph
kcl
mm
mm
mm
mgml
bsa
dtt
glycerol
mm
dctp
dttp
datp
cimmol
activ
calf
thymu
dna
test
compound
indic
concentr
assay
sampl
run
triplic
posit
control
includ
enzym
reaction
allow
proceed
min
follow
transfer
onto
glassfib
filter
plate
subsequ
precipit
trichloroacet
acid
tca
plate
wash
five
time
tca
ethanol
dri
radioact
content
filter
measur
use
determin
extent
inhibit
polymeras
nucleosid
triphosph
ntp
test
cmethyl
utp
sof
cmethyl
gtp
gtp
utp
use
posit
control
singl
nucleotid
incorpor
chain
termin
experi
conduct
analyz
describ
cameron
et
al
cardiomyocyt
assay
human
ip
cardiomyocyt
cellular
dynam
madison
wi
medium
cellular
dynam
seed
plate
cellswel
incub
h
test
posit
control
compound
ad
triplic
incub
continu
day
cell
viabil
measur
xtt
celltit
glo
stain
latter
method
medium
remov
test
plate
replac
celltit
glo
reagent
fresh
medium
incub
rt
min
well
content
transfer
white
plate
luminesc
measur
within
min
wallac
microbeta
trilux
liquid
scintil
counter
bone
marrow
progenitor
cell
inhibit
assay
bone
marrow
progenitor
cell
suspend
plate
cellswel
iscov
modifi
dulbecco
medium
contain
heatinactiv
fb
giant
cell
tumor
condit
medium
bone
marrow
plu
sigma
ngml
recombin
human
ngml
recombin
human
ngml
recombin
human
granulocyt
macrophag
coloni
stimul
factor
gmcsf
r
system
methylcellulos
incub
test
posit
control
compound
day
result
number
coloni
greater
cell
compar
control
well
determin
extent
cytotox
mitochondri
toxic
assay
leukemia
cell
atcc
seed
plate
cellswel
incub
triplic
test
posit
control
compound
rpmi
contain
glucos
fb
mm
lglutamin
plate
incub
day
cell
viabil
measur
xtt
stain
viabil
compar
untreat
cell
determin
valu
separ
cell
incub
triplic
test
compound
glucosefre
rpmi
supplement
mm
galactos
test
compound
dilut
rpmi
contain
glucos
evalu
parallel
follow
incub
h
differenti
biomark
associ
chang
membran
integr
necrosi
measur
fluoresc
nm
cellular
adenosin
triphosph
atp
level
mitochondri
dysfunct
measur
chemiluminesc
use
specif
reagent
provid
promega
mitochondri
toxglo
kit
madison
wi
mitobiogenesi
toxic
assay
cell
prostat
adenocarcinoma
atcc
seed
plate
cellswel
incub
day
triplic
test
posit
control
compound
dmem
supplement
fb
mm
lglutamin
uml
penicillin
streptomycin
one
plate
use
measur
cell
viabil
xtt
stain
cell
remain
two
plate
fix
paraformaldehyd
min
wash
thrice
dpb
acet
acid
ad
min
block
endogen
alkalin
phosphatas
activ
nuclear
dna
encod
complex
ii
sdha
mitochondri
protein
mitochondri
encod
complex
iv
protein
measur
spectrophotometr
use
abcam
mitobiogenesi
elisa
kit
cambridg
uk
per
manufactur
instruct
metabol
incub
triplic
nm
cytochrom
presenc
nadph
regener
system
contain
mm
nadp
mm
mm
uml
dehydrogenas
mm
potassium
phosphat
buffer
ph
h
sampl
extract
addit
volum
icecold
quench
solut
acn
meoh
contain
proper
intern
standard
analyz
lcm
lcmsm
format
potenti
metabolit
similarli
evalu
time
sampl
reaction
without
serv
neg
control
reaction
replac
test
compound
midazolam
bd
bioscienc
franklin
lake
nj
posit
control
inhibit
isozym
incub
duplic
human
liver
microsom
presenc
mm
nadph
mm
potassium
phosphat
ph
contain
mm
probe
substrat
tabl
select
cyp
inhibitor
screen
posit
control
tabl
except
min
min
sampl
incub
min
reaction
termin
addit
meoh
contain
intern
standard
propranolol
quench
sampl
kept
ice
min
centrifug
min
supernat
remov
probe
substrat
metabolit
analyz
lcmsm
decreas
format
metabolit
compar
vehicl
control
use
calcul
valu
anim
welfar
anim
studi
describ
herein
conduct
wuxi
apptec
shanghai
china
strict
complianc
aaalac
intern
nih
guidelin
describ
guid
care
use
laboratori
anim
nation
research
revis
peopl
republ
china
ministri
scienc
technolog
regul
administr
affair
concern
experiment
anim
studi
conduct
full
complianc
protocol
review
approv
wuxi
apptec
institut
anim
care
use
committe
iacuc
prior
studi
initi
iacuc
number
anim
assess
gener
health
member
wuxi
apptec
veterinari
staff
upon
arriv
prior
place
studi
anim
hous
room
control
temperatur
rel
humid
light
cycl
h
artifici
light
h
dark
air
changeshr
provid
manipulativesenrich
toy
rat
pharmacokinet
pk
studi
spraguedawley
rat
obtain
slac
laboratori
anim
co
ltd
shanghai
china
group
hous
acclim
period
individu
hous
studi
provid
ad
libitum
access
purifi
revers
osmosi
ro
water
food
except
fast
overnight
prior
administr
test
articl
h
access
food
restor
two
group
five
rat
singl
sexgroup
administ
singl
dose
mgkg
suspend
cmcna
tween
via
nasogastr
gavag
follow
vehicl
flush
ml
time
nasogastr
tube
volum
dosag
select
close
anticip
highest
dose
use
repeat
oral
dose
toxic
studi
would
permit
accur
assess
plasma
concentr
metabolit
blood
sampl
collect
via
saphen
vein
use
manual
restraint
h
post
dose
three
anim
per
sex
h
post
dose
two
anim
per
sex
blood
sampl
transfer
tube
contain
dipotassium
ethylenediaminetetraacet
acid
dichlorvo
mgml
prevent
coagul
inhibit
esteras
activ
respect
mix
centrifug
x
g
min
prepar
plasma
sampl
quickli
frozen
dri
ice
store
lcmsm
analysi
anim
observ
unusu
advers
clinic
sign
immedi
dose
prior
blood
collect
time
point
sign
note
blood
collect
two
rat
per
group
euthan
inhal
follow
rapid
excis
snapfreez
heart
liver
liquid
nitrogen
frozen
organ
broken
small
piec
approxim
g
tissu
homogen
volum
wv
prechil
homogen
solut
mm
edta
adjust
ph
potassium
hydroxid
meoh
dri
iceethanol
bath
sampl
homogen
extract
volum
intern
standard
solut
ngml
dexamethason
ngml
tolbutamid
ngml
z
yl
methyl
tetrahydrogen
triphosph
mm
dibutyl
acet
acid
dbaa
meoh
supernat
clarifi
centrifug
rpm
min
concentr
plasma
sampl
heart
liver
homogen
supernat
determin
lcmsm
monkey
pk
studi
male
cynomolgu
monkey
obtain
hainan
jingang
laboratori
anim
co
ltd
hainan
china
group
hous
acclim
period
individu
hous
studi
stainless
steel
mesh
cage
provid
ad
libitum
access
ro
water
fed
twice
daili
g
certifi
monkey
diet
daili
beij
vital
keao
feed
co
ltd
beij
china
given
daili
treat
fresh
fruit
addit
environment
enrich
includ
classic
music
cartoon
three
group
monkey
administ
mgkg
powder
fill
empti
porcin
hard
gelatin
capsul
size
monkey
fast
overnight
prior
dose
fed
h
dose
three
dosag
select
provid
assess
dose
proportion
top
two
repres
potenti
dose
repeat
oral
dose
toxic
studi
monkey
lowest
predict
therapeut
relev
pill
gun
use
place
capsul
beyond
root
anim
tongu
mouth
held
loos
close
approxim
sec
allow
move
jaw
swallow
capsul
immedi
follow
capsul
administr
ml
water
given
mouth
mouth
open
ensur
capsul
swallow
blood
sampl
ml
collect
h
three
anim
per
dose
group
h
remain
two
anim
group
time
point
describ
rat
anim
observ
unusu
advers
clinic
sign
immedi
dose
prior
blood
collect
time
point
sign
note
blood
sampl
collect
syring
peripher
blood
vessel
restrain
nonsed
anim
immedi
transfer
prechil
tube
contain
mg
mm
dichlorvo
solut
mix
place
ice
plasma
prepar
centrifug
describ
rat
immedi
centrifug
plasma
sampl
extract
volum
supernat
clarifi
centrifug
rpm
min
store
analyz
lcmsm
describ
blood
collect
two
monkey
per
dose
group
anesthet
intraven
inject
pentobarbit
sodium
mgkg
euthan
describ
rat
sampl
g
liver
heart
tissu
collect
anim
organ
locat
snap
frozen
liquid
nitrogen
homogen
supernat
prepar
describ
rat
tissu
except
one
replic
tissu
homogen
extract
volum
intern
standard
solut
ngml
labetalol
ngml
dexamethason
ngml
tolbutamid
ngml
verapamil
ngml
glyburid
ngml
celecoxib
meoh
acn
vv
determin
concentr
anoth
replic
extract
volum
quantit
determin
concentr
analyt
quantit
lcmsm
describ
lcmsm
analysi
rat
monkey
plasma
tissu
homogen
supernat
analysi
rat
plasma
aliquot
extract
volum
supernat
clarifi
centrifug
rpm
min
sampl
inject
onto
acuiti
beh
mm
column
sciex
api
mass
spectromet
esi
posit
ion
mrm
mode
mobil
phase
formic
acid
fa
mm
ammonium
acet
aa
acn
water
b
fa
mm
aa
acn
water
use
elut
sampl
mlmin
b
min
follow
linear
gradient
b
min
b
min
end
b
min
analysi
rat
plasma
except
sampl
extract
volum
sampl
inject
onto
gemini
x
mm
column
sciex
qtrap
mobil
phase
fa
water
sampl
elut
mlmin
b
min
follow
linear
gradient
b
min
b
min
end
b
min
analysi
monkey
plasma
conduct
analysi
rat
plasma
except
freshli
prepar
plasma
sampl
extract
prior
storag
describ
aliquot
analyz
lcmsm
analysi
rat
tissu
homogen
supernat
aliquot
dilut
water
inject
onto
agil
zorbax
extend
mm
column
sciex
api
mass
spectromet
esi
posit
ion
mrm
mode
mobil
phase
ammonia
mm
dbaa
water
vv
b
mm
dimethylhexylamin
dmha
mm
aa
acn
water
use
elut
sampl
mlmin
b
min
follow
linear
gradient
b
min
isocrat
elut
b
min
linear
gradient
b
min
end
b
min
analysi
monkey
tissu
homogen
supernat
except
sampl
inject
volum
attempt
measur
tissu
level
potenti
form
tp
includ
triphosph
triphosph
also
use
method
analysi
monkey
tissu
homogen
supernat
analysi
analyt
monkey
plasma
except
supernat
dilut
water
prior
analysi
use
sciex
api
mass
spectromet
analysi
monkey
tissu
homogen
supernat
aliquot
dilut
water
inject
onto
acuiti
hss
mm
column
sciex
api
mass
spectromet
esi
posit
ion
mrm
mode
mobil
phase
fa
mm
aa
water
b
fa
mm
aa
acn
water
use
elut
sampl
mlmin
b
min
follow
linear
gradient
b
min
b
min
end
isocrat
elut
b
min
pk
data
analysi
plasma
concentr
anim
use
tissu
collect
ratssexdos
group
male
monkeysdos
group
subject
noncompartment
pharmacokinet
analysi
use
phoenix
winnonlin
softwar
version
pharsight
mountain
view
ca
linearlog
trapezoid
rule
appli
obtain
pk
paramet
